Literature DB >> 25124778

Oral therapy for multiple myeloma: ixazomib arriving soon.

Philippe Moreau1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25124778      PMCID： PMC4133498          DOI： 10.1182/blood-2014-06-581611

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

Review 1.  Proteasome inhibitors in multiple myeloma: 10 years later.

Authors:  Philippe Moreau; Paul G Richardson; Michele Cavo; Robert Z Orlowski; Jesús F San Miguel; Antonio Palumbo; Jean-Luc Harousseau
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

Review 2.  Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

Authors:  Andrzej J Jakubowiak
Journal:  Cancer Treat Rev       Date:  2014-03-01       Impact factor: 12.111

3.  Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Authors:  Paul G Richardson; Rachid Baz; Michael Wang; Andrzej J Jakubowiak; Jacob P Laubach; R Donald Harvey; Moshe Talpaz; Deborah Berg; Guohui Liu; Jiang Yu; Neeraj Gupta; Alessandra Di Bacco; Ai-Min Hui; Sagar Lonial
Journal:  Blood       Date:  2014-06-11       Impact factor: 22.113

4.  Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Authors:  Shaji K Kumar; William I Bensinger; Todd M Zimmerman; Craig B Reeder; James R Berenson; Deborah Berg; Ai-Min Hui; Neeraj Gupta; Alessandra Di Bacco; Jiang Yu; Yaping Shou; Ruben Niesvizky
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

Review 5.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Authors:  E M Ocio; P G Richardson; S V Rajkumar; A Palumbo; M V Mateos; R Orlowski; S Kumar; S Usmani; D Roodman; R Niesvizky; H Einsele; K C Anderson; M A Dimopoulos; H Avet-Loiseau; U-H Mellqvist; I Turesson; G Merlini; R Schots; P McCarthy; L Bergsagel; C S Chim; J J Lahuerta; J Shah; A Reiman; J Mikhael; S Zweegman; S Lonial; R Comenzo; W J Chng; P Moreau; P Sonneveld; H Ludwig; B G M Durie; J F S Miguel
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

6.  Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Authors:  Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau
Journal:  Lancet Oncol       Date:  2011-04-18       Impact factor: 41.316

Review 7.  The emerging role of carfilzomib combination therapy in the management of multiple myeloma.

Authors:  Philippe Moreau
Journal:  Expert Rev Hematol       Date:  2014-02-12       Impact factor: 2.929

8.  U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

Authors:  Thomas M Herndon; Albert Deisseroth; Edvardas Kaminskas; Robert C Kane; Kallappa M Koti; Mark D Rothmann; Bahru Habtemariam; Julie Bullock; Jeffrey D Bray; Jessica Hawes; Todd R Palmby; Josephine Jee; William Adams; Houda Mahayni; Janice Brown; Angelica Dorantes; Rajeshwari Sridhara; Ann T Farrell; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2013-06-17       Impact factor: 12.531

9.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

Authors:  Erik Kupperman; Edmund C Lee; Yueying Cao; Bret Bannerman; Michael Fitzgerald; Allison Berger; Jie Yu; Yu Yang; Paul Hales; Frank Bruzzese; Jane Liu; Jonathan Blank; Khristofer Garcia; Christopher Tsu; Larry Dick; Paul Fleming; Li Yu; Mark Manfredi; Mark Rolfe; Joe Bolen
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701
  9 in total
  5 in total

Review 1.  Ixazomib: First Global Approval.

Authors:  Matt Shirley
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

2.  Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.

Authors:  Jonghoon Park; Eok Park; Cheol-Kyu Jung; Seung-Wan Kang; Byung Gyu Kim; Youngjoo Jung; Tae Hun Kim; Ji-Young Lim; Sung-Eun Lee; Chang-Ki Min; Kwang-Ai Won
Journal:  BMC Cancer       Date:  2016-03-24       Impact factor: 4.430

Review 3.  Recent advances in multiple myeloma: a Korean perspective.

Authors:  Junshik Hong; Jae Hoon Lee
Journal:  Korean J Intern Med       Date:  2016-09-01       Impact factor: 2.884

4.  Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection.

Authors:  Milly M Choy; Summer L Zhang; Vivian V Costa; Hwee Cheng Tan; Sophie Horrevorts; Eng Eong Ooi
Journal:  PLoS Negl Trop Dis       Date:  2015-11-13

5.  The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.

Authors:  Samantha Hinsley; Katrina Walker; Debbie Sherratt; Lucy Bailey; Sadie Reed; Louise Flanagan; Sophie McKee; Fiona Brudenell Straw; Bryony Dawkins; David Meads; Holger W Auner; Martin F Kaiser; Mark Cook; Sarah Brown; Gordon Cook
Journal:  Trials       Date:  2020-10-02       Impact factor: 2.279
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.